The virome in hematology-Stem cell transplantation and beyond.

abstract：:Mantle cell lymphoma (MCL) has only recently been recognized as a separate biologically defined lymphoma entity. Due to its low incidence, many reports on clinical prognostic factors are limited by small patient numbers. The MCL International Prognostic Index (MIPI) was developed using data of more than 400 patients t...

journal_title：Seminars in hematology

authors： Hoster E

更新日期：2011-07-01 00:00:00

abstract：:Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder in which the patient's immune system reacts with a platelet autoantigen(s) resulting in thrombocytopenia due to immune-mediated platelet destruction and/or suppression of platelet production. Platelet membrane proteins, for reasons that are unclea...

journal_title：Seminars in hematology

authors： McMillan R

更新日期：2007-10-01 00:00:00

abstract：:Iron is a vitally important element in mammalian metabolism because of its unsurpassed versatility as a biologic catalyst. However, when not appropriately shielded or when present in excess, iron plays a key role in the formation of extremely toxic oxygen radicals, which ultimately cause peroxidative damage to vital c...

journal_title：Seminars in hematology

authors： Ponka P

更新日期：2002-10-01 00:00:00

abstract：:Imatinib (Gleevec) (formerly STI571) competitively targets the adenosine 5-triphosphate (ATP) binding site of the kinase domain of ABL and was recently approved for the treatment of chronic myeloid leukemia (CML). Point mutations occurring in the kinase domain of BCR-ABL have been identified as a cause of imatinib res...

journal_title：Seminars in hematology

authors： Roche-Lestienne C,Preudhomme C

更新日期：2003-04-01 00:00:00

abstract：:Acute promyelocytic leukemia (APL) is characterized by reciprocal chromosomal translocations that always Involve the retinoic acid receptor-alpha (RARalpha) gene on chromosome 17. RARalpha variably fuses to the PML, PLZF, NPM, NuMA, and STAT 5b genes (X genes), leading to the generation of X-RARalpha and RARalpha-X fu...

journal_title：Seminars in hematology

authors： Rego EM,Pandolfi PP

更新日期：2001-01-01 00:00:00

abstract：:For the majority of hematologic malignancies allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment option. Sibling donors have been the standard for adult patients. Since there is not a suitable family donor for all patients, the need for alternative donors for HCT is great. Fortunately, t...

journal_title：Seminars in hematology

authors： Sebastian Schäfer H,Finke J

更新日期：2016-04-01 00:00:00

abstract：:In early studies, recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) has been found to reduce the depth and duration of granulocytopenia in the settings of cancer chemotherapy and autologous bone marrow transplantation. In patients with myelodysplastic syndrome or aplastic anemia. GM-CSF has p...

journal_title：Seminars in hematology

authors： Gutterman J,Vadhan-Raj S,Logothetis C,Anaissle E,Estey E,Talpaz M,Kurzrock R

更新日期：1990-07-01 00:00:00

abstract：:Inhibition of antibody-coated platelet destruction in patients with immune thrombocytopenic purpura (ITP) is a well-known mechanism of treatment effect. A number of interventions that would ameliorate the thrombocytopenic effect of ITP patient plasma when infused into normal recipients were demonstrated in 1965. Subse...

journal_title：Seminars in hematology

authors： Bussel JB

更新日期：2000-07-01 00:00:00

abstract：:Trauma is rapidly replacing stroke and cardiovascular disease as a leading cause of death in Western countries such as the United States, and almost a third (30%) of trauma deaths are due to blood loss. Although the new intervention strategies that have been developed and adopted by emergency care staff have reduced t...

journal_title：Seminars in hematology

authors： Hoyt DB

更新日期：2004-01-01 00:00:00

abstract：:The immunomodulatory drug (IMiD) lenalidomide is a more potent immunomodulator than thalidomide with respect to its effects on cytokine modulation and increased T-cell proliferation. Of all the IMiDs, clinical trial data are most mature for lenalidomide. In phase I studies, dose-limiting toxicities of lenalidomide wer...

journal_title：Seminars in hematology

authors： Richardson P

更新日期：2005-10-01 00:00:00

abstract：:The standard treatment of multiple myeloma is systemic chemotherapy. Despite 30 years of drug development in myeloma, there are no new drug regimens significantly superior to melphalan and prednisone. In addition, phase II studies of new drugs in myeloma have been disappointing, with low response rates and no prolonga...

journal_title：Seminars in hematology

authors： Kraut EH,Ju R,Muller M

更新日期：1998-07-01 00:00:00

abstract：:Purine analogues have been shown to be active in a variety of B- and T-cell malignancies. Among them, pentostatin is also a tight binding inhibitor of adenosine deaminase (ADA), a key enzyme of purine metabolism. ADA is present in all human tissues, with the highest levels in the lymphoid system. Early clinical trials...

journal_title：Seminars in hematology

authors： Ho AD,Hensel M

更新日期：2006-04-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is a hematopoietic disorder characterized by malignant expansion of bone marrow stem cells. Currently, the only unequivocally curative treatment for CML is allogeneic stem cell transplant. Unfortunately, a large proportion of CML patients are ineligible for such treatment and alternative...

journal_title：Seminars in hematology

authors： Barnes DJ,Melo JV

更新日期：2003-01-01 00:00:00

abstract：:Anemia is frequently diagnosed in patients with cancer and its treatment is an important clinical problem. The deficiency in red blood cells (RBCs) can be a debilitating problem, and anemia correlates with poor performance status, deteriorates quality of life, and may negatively influence the prognosis of cancer patie...

journal_title：Seminars in hematology

authors： Beutel G,Ganser A

更新日期：2007-07-01 00:00:00

abstract：:Immune thrombocytopenia (ITP) is a bleeding disorder characterized by low platelet counts due to decreased platelet production as well as increased platelet destruction by autoimmune mechanisms. A shift toward Th1 and possibly Th17 cells together with impaired regulatory compartment, including T-regulatory (Tregs) and...

journal_title：Seminars in hematology

authors： Yazdanbakhsh K,Zhong H,Bao W

更新日期：2013-01-01 00:00:00

abstract：:The B-cell receptor (BCR) is of critical importance for normal B cells and for the majority of B-cell malignancies, especially chronic lymphocytic leukemia (CLL). The two major subsets of CLL are biologically distinct, being derived from B cells at different stages of differentiation and carrying unmutated (U-CLL) or ...

journal_title：Seminars in hematology

authors： Stevenson FK,Forconi F,Packham G

更新日期：2014-07-01 00:00:00

abstract：:From work particularly In the last two decades of the century, the cell populations forming blood cells can now be purified and cultured clonally so that blood cell formation can be analyzed in vitro. A large number of specific regulators of this process have been identified and mass-produced in recombinant form. Thre...

journal_title：Seminars in hematology

authors： Metcalf D

更新日期：1999-10-01 00:00:00

abstract：:The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, procarbazine (COP-BLAM) programs of combination chemotherapy were administered to patients with advanced diffuse large cell lymphoma. The original COP-BLAM programs were designed to deliver intense multidrug therapy maximizing tumor kill. COP-BLAM ...

journal_title：Seminars in hematology

authors： Coleman M,Armitage JO,Gaynor M,McDermott D,Weisenburger DD,Adler K,Beshevkin M,Silver RT,Reisman AM,Pasmantier MW

更新日期：1988-04-01 00:00:00

abstract：:The presence or absence of minimal residual disease (MRD) in patients with multiple myeloma (MM) has emerged as a useful marker to determine the depth of remission. MRD negativity as an endpoint has been shown to be associated with improved progression-free survival in many studies. MRD detection is therefore part of ...

journal_title：Seminars in hematology

authors： Waldschmidt JM,Anand P,Knoechel B,Lohr JG

更新日期：2018-01-01 00:00:00

abstract：:It is now well accepted that a subgroup of patients with myelodysplastic syndromes (MDS) can recover from pancytopenia following immunosuppressive treatment (IST). For many years immunosuppression with antilymphocyte antibodies has been a standard treatment approach for patients with severe aplastic anemia (SAA). The ...

journal_title：Seminars in hematology

authors： Parikh AR,Olnes MJ,Barrett AJ

更新日期：2012-10-01 00:00:00

abstract：:These two issues of the Seminars in Hematology will provide the physician the necessary knowledge to help make sense of this somewhat confusing array of diseases. The subdivisions of MDS reflect the precision of our techniques of dissection, with morphological and histochemical analyses forming the foundation to ident...

journal_title：Seminars in hematology

authors： Koeffler HP

更新日期：1996-04-01 00:00:00

abstract：:The central hypothesis of our laboratory research program in large granular lymphocyte (LGL) leukemia is that leukemic LGL represent antigen-driven cytotoxic T lymphocytes (CTL) with characteristics of dysregulated apoptosis. The clinical features of LGL leukemia highlight the association of autoimmune diseases such a...

journal_title：Seminars in hematology

authors： Epling-Burnette PK,Loughran TP Jr

更新日期：2003-07-01 00:00:00

abstract：:The value of prophylaxis against venous thromboembolism (VTE) is increasingly accepted in most surgical specialties, although the potential reduction in fatal pulmonary embolism has recently been questioned. The burden of VTE in hospital patients nevertheless remains high, partly attributable to underuse of thrombopro...

journal_title：Seminars in hematology

authors： Wille-Jørgensen P

更新日期：2001-04-01 00:00:00

abstract：:Though peripheral T-cell lymphoma (PTCL) is an area of significant unmet therapeutic need, a number of new treatment options are available for patients, especially those with relapsed or refractory disease. A plethora of drugs are now in development for PTCL, but drugs that truly target novel disease biology are notic...

journal_title：Seminars in hematology

authors： O'Connor OA

更新日期：2010-04-01 00:00:00

abstract：:Infectious diseases are the leading causes of death in patients with multiple myeloma (MM). Major changes have occurred in the spectrum of infections paralleling the changes in the treatment of MM. Bacteria (particularly gram-negative organisms) are the most frequent etiologic agents, and invasive fungal infections ca...

journal_title：Seminars in hematology

authors： Nucci M,Anaissie E

更新日期：2009-07-01 00:00:00

abstract：:The successful clinical development of thalidomide, bortezomib, and lenalidomide not only transformed the therapeutic management of multiple myeloma (MM) but also catalyzed a renewed interest in the development of additional classes of novel agents for this disease. This review focuses on a series of new therapeutics ...

journal_title：Seminars in hematology

authors： Mitsiades CS,Hideshima T,Chauhan D,McMillin DW,Klippel S,Laubach JP,Munshi NC,Anderson KC,Richardson PG

更新日期：2009-04-01 00:00:00

abstract：:The farnesyltransferase inhibitors (FTIs) have been shown in early clinical trials to elicit antitumor actions in a broad range of solid and hematologic malignancies. The mechanism of FTI action involves blockade of farnesyltransferase, an enzyme implicated in multiple cell-signaling pathways involved in proliferation...

journal_title：Seminars in hematology

authors： Cortes JE,Kurzrock R,Kantarjian HM

更新日期：2002-07-01 00:00:00

abstract：:Anemia is frequent and significantly adds to the morbidity of cancer patients, and has been associated with decreased quality of life (QOL). Three open-label community-based studies of epoetin alfa in cancer-related anemia (two using three-times-weekly dosing and one using once-weekly dosing) in more than 7,000 patien...

journal_title：Seminars in hematology

authors： Soignet S

更新日期：2000-10-01 00:00:00

abstract：:A new high-purity recombinant factor VIII preparation has been developed for the treatment of hemophilia A. Structurally, this factor VIII preparation, B-domain deleted recombinant factor VIII (BDDrFVIII), differs from other recombinant and plasma-derived factor VIII preparations in that most of the B-domain has been ...

journal_title：Seminars in hematology

authors： Sandberg H,Almstedt A,Brandt J,Castro VM,Gray E,Holmquist L,Lewin M,Oswaldsson U,Mikaelsson M,Jankowski MA,Bond M,Scoble HA

更新日期：2001-04-01 00:00:00

abstract：:The availability of antibodies reactive with antigens expressed only by hematopoietic cells has provided clinical investigators with new tools for use in developing therapies for acute myeloid leukemia (AML). Studies performed to date have investigated the use of such antibodies in an unmodified state, combined with p...

journal_title：Seminars in hematology

authors： Appelbaum FR

更新日期：1999-10-01 00:00:00